Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod Cognitive Benefits in MS
NCT06334094Phase 4Withdrawn
- Sponsor
- The University of Texas at Dallas
- Start
- Jun 2024
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ozanimod in relapsing-remitting multiple sclerosis (RRMS), sponsored by The University of Texas at Dallas. Planned start Jun 2024; status: withdrawn.
02
Drugs
ozanimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT06334094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06334094.